However, recent studies have evaluated the prognostic role of serum inflammatory markers, including C-reactive protein (CRP), serum albumin, neutrophil–lymphocyte ratio (NLR), platelet–lymphocyte ratio (PLR), and lymphocyte–monocyte ratio (LMR), because of the association between cancer development and prognosis and systemic inflammation for many urologic malignancies [9,11,12,13,14]. This evidence concerns the gene CRP and cancer.